{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.64","value":"68.2"},{"groupId":"OG001","spread":"0.66","value":"68.0"},{"groupId":"OG002","spread":"0.65","value":"67.4"}]}],"title":"prior to treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.53","value":"73.8"},{"groupId":"OG001","spread":"0.56","value":"71.1"},{"groupId":"OG002","spread":"0.54","value":"70.9"}]}],"title":"prior to cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.54","value":"76.0"},{"groupId":"OG001","spread":"0.56","value":"74.3"},{"groupId":"OG002","spread":"0.58","value":"73.8"}]}],"title":"prior to cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.62","value":"80.6"},{"groupId":"OG001","spread":"0.62","value":"80.5"},{"groupId":"OG002","spread":"0.58","value":"79.9"}]}],"title":"prior to cycle 13"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.73","value":"77.6"},{"groupId":"OG001","spread":"0.71","value":"79.1"},{"groupId":"OG002","spread":"0.66","value":"78.6"}]}],"title":"prior to cycle 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.78","value":"75.8"},{"groupId":"OG001","spread":"0.75","value":"77.6"},{"groupId":"OG002","spread":"0.75","value":"77.8"}]}],"title":"6 months followup"}],"denoms":[{"counts":[{"groupId":"OG000","value":"625"},{"groupId":"OG001","value":"625"},{"groupId":"OG002","value":"623"}],"units":"Participants"}],"description":"Estimated least squares means from a mixed module of Quality of Life (QOL) scores at each assessment point, adjusted for baseline score and patient's age. Note: The range of possible scores of the FACT-O TOI is 0 - 104 for all treatment groups and at all visits. A higher score indicates better QOL. Baseline mean scores are raw means.","dispersionType":"Standard Deviation","groups":[{"description":"Control therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus placebo (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received placebo every 3 weeks.","id":"OG000","title":"Arm I (Placebo, Paclitaxel, Carboplatin)"},{"description":"Bevacizumab-initiation therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus bevacizumab, 15 mg/kg (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received placebo every 3 weeks.","id":"OG001","title":"Arm II (Placebo, Paclitaxel, Carboplatin, Bevacizumab)"},{"description":"Bevacizumab-throughout therapy:\n\nCycles 1-6 received paclitaxel, 175 mg/m2 plus carboplatin AUC 6 plus bevacizumab, 15 mg/kg (starting in cycle 2) every 3 weeks.\n\nCycles 7-22 received bevacizumab, 15 mg/kg every 3 weeks.","id":"OG002","title":"Arm III (Paclitaxel, Carboplatin, Bevacizumab)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Number of valid QOL assessments do not total number of patients randomized in study.","reportingStatus":"POSTED","timeFrame":"At baseline, 9, 18, 36, 60, and 84 weeks","title":"Impact on Quality of Life Measured by the Functional Assessment of Cancer Therapy-Ovary Trial Outcome Index (FACT-O TOI)","type":"SECONDARY","unitOfMeasure":"units on a scale"}